Treatment patterns and effectiveness outcomes in patients with relapsed/refractory classical Hodgkin’s lymphoma who received autologous and/or allogenic stem cell transplantation

While classical Hodgkin’s lymphoma (cHL) is seeing increasing survival rates, patients with multiple relapses (including patients with transplant), require several lines of treatment. Treatment patterns and overall survival (OS) for relapsed/refractory (R/R) cHL patients pre- and post-transplant in the real world are currently less understood. The purpose of this study was to evaluate patient characteristics, treatment patterns and OS of R/R cHL patients who received autologous (auto-SCT) and/or allogenic (allo-SCT) stem cell transplants. The study concluded that in the real-world setting, over half of R/R cHL patients received auto-SCT (mainly between their first and second R/R event) while few patients received allo-SCT. Patients with auto-SCT had a longer survival compared to those without a transplant. There appears to be no clear standard of care post-transplant, particularly in later lines of therapy, highlighted by the range of regimens

Read More